the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections.

A Cohort Study to Assess the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections

Pharmacological treatment of physiologic Gastro-esophageal Reflux disease (GERD) is excessive in France, as 65%-85% of children below 11 years are being treated, frequently with Proton Pump Inhibitors (PPIs) PPI have been associated, in adults, with an increase of infection rate but data in pediatry are scarce, especially in community medecine. Recently a study conducted in England brought up controversial results suggesting that the use of PPIs can be associated with a reduced risk of community acquired pneumonia.

Our study was aimed to assess, on a population-based database, the association between PPI prescription and community infections in children of 11 years or under.

Inclusion Criteria:

• Children aged 11 years or below with at least 2 consultations during the follow up

Exclusion Criteria:

• chronic pulmonary or cardiac
• muscoviscidosis
• immunodeficiency
• H. pylori infection
• Diabetes
• Denutrition
• known digestive upper tract malformation